Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany.
Age distribution
Chemotherapy
Gastric cancer
Perioperative
Tumour localisation
Validity
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 May 2020
15 May 2020
Historique:
received:
27
11
2019
revised:
18
03
2020
accepted:
08
04
2020
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
29
5
2020
Statut:
ppublish
Résumé
Neoadjuvant/perioperative chemotherapy is the recommended treatment for advanced stages of gastric cancer (> T2, N+) before tumour resection in many European guidelines. However, there is no consensus as to whether perioperative chemotherapy is as effective in distal as in proximal tumours, in addition to a relevant uncertainty concerning appropriate treatment modalities for elderly patients. To investigate the role of perioperative chemotherapy in advanced gastric cancer in patients from a German tertiary clinic with respect to efficacy, localisation, and age. We performed a retrospective analysis of 158 patients from our clinic with adenocarcinoma of the stomach or the gastroesophageal junction who underwent resection between 2008 and 2016. The data were evaluated particularly in relation to patient age, tumour site, and perioperative therapy. Administration of perioperative chemotherapy did not lead to a significant survival advantage in our study population. The 5-year survival rates were 40% for patients who received perioperative chemotherapy and 29% for the group without perioperative chemotherapy ( This analysis reconfirms our previous data concerning the effectiveness of perioperative chemotherapy for advanced gastric cancer. There is reasonable doubt that the quality of the existing randomized controlled trials is sufficient to generally justify perioperative chemotherapy in patients with advanced gastric cancer independent of tumour localization or age.
Sections du résumé
BACKGROUND
BACKGROUND
Neoadjuvant/perioperative chemotherapy is the recommended treatment for advanced stages of gastric cancer (> T2, N+) before tumour resection in many European guidelines. However, there is no consensus as to whether perioperative chemotherapy is as effective in distal as in proximal tumours, in addition to a relevant uncertainty concerning appropriate treatment modalities for elderly patients.
AIM
OBJECTIVE
To investigate the role of perioperative chemotherapy in advanced gastric cancer in patients from a German tertiary clinic with respect to efficacy, localisation, and age.
METHODS
METHODS
We performed a retrospective analysis of 158 patients from our clinic with adenocarcinoma of the stomach or the gastroesophageal junction who underwent resection between 2008 and 2016. The data were evaluated particularly in relation to patient age, tumour site, and perioperative therapy.
RESULTS
RESULTS
Administration of perioperative chemotherapy did not lead to a significant survival advantage in our study population. The 5-year survival rates were 40% for patients who received perioperative chemotherapy and 29% for the group without perioperative chemotherapy (
CONCLUSION
CONCLUSIONS
This analysis reconfirms our previous data concerning the effectiveness of perioperative chemotherapy for advanced gastric cancer. There is reasonable doubt that the quality of the existing randomized controlled trials is sufficient to generally justify perioperative chemotherapy in patients with advanced gastric cancer independent of tumour localization or age.
Identifiants
pubmed: 32461787
doi: 10.4251/wjgo.v12.i5.559
pmc: PMC7235186
doi:
Types de publication
Journal Article
Langues
eng
Pagination
559-568Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Références
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
World J Surg. 1993 Mar-Apr;17(2):256-61; discussion 261-2
pubmed: 8511923
Eur J Surg Oncol. 2004 Aug;30(6):643-9
pubmed: 15256239
World J Gastroenterol. 2010 Feb 21;16(7):868-74
pubmed: 20143466
J Clin Oncol. 2010 Dec 10;28(35):5210-8
pubmed: 21060024
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
BMJ Open Gastroenterol. 2017 Sep 14;4(1):e000138
pubmed: 29177062
J Gastric Cancer. 2015 Mar;15(1):10-8
pubmed: 25861518
Z Gastroenterol. 2011 Apr;49(4):461-531
pubmed: 21476183
Gut. 2011 Nov;60(11):1449-72
pubmed: 21705456
Ann Gastroenterol Surg. 2018 Aug 29;2(6):400-405
pubmed: 30460342
J Gastric Cancer. 2019 Jun;19(2):202-211
pubmed: 31245165
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Hepatogastroenterology. 2013 Oct;60(127):1822-4
pubmed: 24624448
J Gastric Cancer. 2018 Mar;18(1):69-81
pubmed: 29629222
J Gastric Cancer. 2014 Mar;14(1):39-46
pubmed: 24765536